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Abstract
Background: Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and
during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D
supplementation, in the follow-up period after diagnosis and surgical resection of the primary tumor, has a
protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates
with vitamin D levels in serum and Vitamin D Receptor immunoreactivity in the primary tumor.
Methods/design: This study is a multicenter randomized double blind placebo- controlled phase III trial. Patients
between the age of 18 and 80 years diagnosed and treated surgically for a melanoma stage IB-III are eligible for
randomization in a 1:1 ratio to active treatment or placebo. The study drug is taken each month and consists of
either 100,000 International Unit cholecalciferol or arachidis oleum raffinatum used as a placebo. The primary
endpoint is relapse free survival. The secondary endpoints are 25 hydroxyvitamin D3 serum levels at diagnosis
and at 6 month intervals, melanoma subtype, melanoma site and stage of melanoma at diagnosis according
to the 2009 American Joint Committee on Cancer melanoma staging and classification. At randomization a
bloodsample is taken for DNA analysis. The study is approved by the local Ethics Committees.
Discussion: If we can confirm our hypothesis that vitamin D supplementation after removal of the tumor has a
protective effect on relapse of cutaneous malignant melanoma we may reduce the burden of CMM at several
levels. Patients, diagnosed with melanoma may have a better clinical outcome and improved quality of life. There
will be a decrease in health care costs related to treatment of metastatic disease and there will be a decrease in
loss of professional years, which will markedly reduce the economic burden of the disease.
Trial registration: Clinical Trial.gov, NCT01748448, 05/12/2012
Keywords: Melanoma, Vitamin D, Randomized controlled trial, Safety, Secondary prevention
Background
Cutaneous malignant melanoma: risk factors for
development and progression, current knowledge
Cutaneous malignant melanoma (CMM) is the 7th most
frequent tumor in males and 4th most frequent tumor
in females in Belgium [1]. It only accounts for 4% of all
malignant tumors of the skin, but it is responsible for
80% of the skin cancer related deaths [2, 3].
In 2013 the Belgian CMM incidence was 19.9 cases per
100,000 men (Crude Rate) and 18.5 cases per 100,000
women (Crude Rate) [4]. During the last decade’s inci-
dence rates have been rising in many countries within
white populations and it is expected that the incidence
will further increase the coming years [5, 6]. CMM arises
from a stepwise transformation of melanocytes in the skin,
with subsequent superficial and deep invasion ultimately
forming metastasis [3]. Several risk factors have been
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linked to the development of CMM. The strongest risk
factors for melanoma are a family history of melanoma,
multiple benign or atypical naevi and a previous melan-
oma. Immunosuppression, low phototype and exposure to
ultraviolet light are additional risk factors [7]. The most
important clinicopathological subtypes of melanoma are
superficial spreading malignant melanoma, nodular ma-
lignant melanoma, lentigo maligna melanoma and acro-
lentiginous malignant melanoma. Diagnostic signs are
progressive asymmetrical enlargement of a pigment lesion
which also demonstrates irregularity in colour and irregu-
larity in shape. Different risk factors are associated with
different subtypes of CMM and different locations of ma-
lignant melanoma [8]. Different subtypes of malignant
melanomas show also a significant genetic heterogeneity.
The most important predictor for melanoma relapse and
melanoma specific survival is Breslow thickness of the
primary tumor at diagnosis [9]. This is a histological
characteristic of the tumor and refers to the thickness of
the tumor, measured as the distance between the granu-
lar layer of the epidermis and the deepest tumor cell in
millimeters. Additional independent prognostic factors
for survival are primary tumor ulceration and primary
tumor mitotic rate according to the 2009 American Joint
Committee on Cancer (AJCC) melanoma classification.
Other known predictive prognostic factors are presence
and distribution of tumor infiltrating lymphocytes,
tumor site, sex and social deprivation [9, 10]. The overall
survival of CMM is better for earlier stages of the dis-
ease, however relapse poses a significant threat even for
patients with limited disease. For this patient population
we need an adjuvant treatment strategy which is cost/ef-
ficient, feasible and safe. Vitamin D supplementation is
such a potential adjuvant treatment strategy, since vita-
min D may protect against tumor progression through
its pleiotropic anticancer effects via binding to its Vitamin
D Receptor (VDR) [11].
Vitamin D status: current knowledge
Vitamin D, a fat-soluble seco-steroid, has two sources.
The main source, vitamin D3 (cholecalciferol), is the
skin. The other source, vitamin D2 (ergocalciferol)
and D3, is exogenous and is ingested via dietary in-
take or supplements. The endogenous pathway is the
most important source of vitamin D for humans. 7-
dehydrocholesterol (7-DHC), a provitamin in the epider-
mis, is photoactivated by ultraviolet B (UVB) radiation
into provitamin D3. A series of modifications in the skin,
liver and kidneys metabolizes vitamin D2 and vitamin
D3 (dietary and endogenous) into the active substance
1α,25 dihydroxyvitamin D3 (calcitriol, 1,25(OH)2D3).
1,25(OH)2D3 and retinoid X receptor form a heterodi-
mer and have an effect on gene expression by binding to
the vitamin D receptor [11]. This is illustrated in Fig. 1.
The active metabolite of vitamin D, 1,25(OH)2D3,
demonstrates relevant anti-cancer effects on melanoma
cells. It has antiproliferative, differentiating and proa-
poptotic effects, but also inhibitory effects on tumour
invasion and metastasis [12, 13]. These pleiotropic anti-
cancer effects are mediated by the VDR. Serum concen-
tration of 25 hydroxy vitamin D3 (25(OH)D3) is the
best indicator of the vitamin D status, which is deter-
mined by UVB induced production of vitamin D in the
skin, dietary intake and vitamin D supplementation
[14]. In addition vitamin D status may also be influ-
enced by genetic variants of certain proteins involved
in the vitamin D pathway [15]. A serum concentration
of 25(OH)D3 below 10 ng/ml (<25 nmol/L) is consid-
ered as vitamin D deficient, and a serum concentration
below 20 ng/ml (<50 nmol/L) as vitamin D insufficient.
The optimal level for health is believed to be reached at
30 ng/ml (75 nmol/L). Toxic levels are in the range of
100–150 ng/ml (or 250–375 nmol/L). Vitamin D sup-
plementation in the form of vitamin D3 can raise
25(OH)D3 concentrations and is safe when given in a
single monthly dose of 100,000 IU during a year and
given in an oral loading dose of 500,000 IU followed by
an oral dose of 50,000 IU monthly for 2 years [16, 17].
Current recommendation for additional vitamin D
intake via supplements is 1000 IU/d. Norman and
Bouillon showed a good safety profile for this amount
in more than 50,000 subjects over several years [18].
25(OH)D3 concentrations reach a plateau after 3 months,
when vitamin D3 supplementation is given monthly
in a dose of 1000 IU/d [19]. There is an established
proof of concept that vitamin D has an anticancer ef-
fect on CMM.
Already 30 years ago, in vitro studies demonstrated
an anti-melanoma activity of 1,25(OH)2D3 with effects
on cellular growth, differentiation, apoptosis, malignant
cell invasion and metastasis [20]. These processes are
possibly being mediated through the expression of VDR
in malignant melanoma cells and primary melanoma
tissue [21]. In vivo vitamin D has also shown to sup-
press growth of human malignant melanoma derived
xenografts in immunosuppressed mice [22].
Previous studies have investigated the effect of vita-
min D serum levels on CMM outcome, at diagnosis
and/or during the follow up period after treatment [9,
23]. However conflicting results were obtained from
these studies. The study of Newton Bishop et al. indi-
cated that high vitamin D levels at diagnosis may have
a protective effect on malignant melanoma outcome
[9]. The study of Saiag et al. showed that the variabil-
ity of 25(OH)D3 during follow-up of melanoma pa-
tients, but not the level at diagnosis per se was an
independent prognostic marker [23]. A recent study
showed that the associations of lower levels of vitamin
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D with poorer overall survival, melanoma-specific sur-
vival and disease-free survival were independent from
the association between lower vitamin D and higher
C-reactive protein [24].To further elucidate a possible
protective effect of vitamin D on melanoma outcome
we initiated a multicenter randomized double blind
placebo-controlled phase III trial to assess the effect
of vitamin D supplementation on CMM relapse in the
follow-up period after diagnosis and surgery of the
primary tumor.
Primary objectives
The primary endpoint for this study is relapse-free sur-
vival. We will test the hypothesis that vitamin D supple-
mentation after removal of the primary tumor has a
protective effect on CMM relapse. We will also assess
the immunohistochemical expression of VDR in the pri-
mary tumor and its possible correlation with relapse.
Secondary objectives
Vitamin D levels at diagnosis will be correlated with
melanoma site, subtype and stage at diagnosis. We will
monitor increases in vitamin D levels after supplementa-
tion. This will allow us to assess whether every patient is
characterized by the same increase in vitamin D or
whether serum levels following intake depend on the
genetic variability in the vitamin D pathway and whether
this genetic variability correlates with stage at diagnosis.
Furthermore, we will investigate whether VDR immu-
noreactivity correlates with stage at diagnosis.
Methods and design
Study design
This is a double blind placebo-controlled phase III mul-
ticenter study conducted at the University Hospitals
Leuven, the University Hospitals of Antwerp, the Centre
Hospitalier Universitaire de Liège in Belgium and at the
Fig. 1. Physiology of Vitamin D, reprinted from Melanoma and vitamin D, Molecular Oncology 5, Field S., Newton-Bishop JA., 2011; 197-214 [11].
Copyright 2016, with permission from Elsevier
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Medical and Health Science Center at the University of
Debrecen in Hungary.
Overview of study flow
There is a random assignment of patients in a 1:1 ratio.
The treatment group receives a monthly oral dose of
100,000 IU of vitamin D (4 ml of D-Cure™) while the
control group receives a monthly oral dose of placebo
(4 ml of arachidis oleum). To overcome seasonal influ-
ences on baseline characteristics, a block randomization
method stratifies on center and the time of diagnosis.
Per center there are 3 strata: patients diagnosed within
6 months, between 6 and 12 months before start of the
study and newly diagnosed patients (Fig. 2).
Participants
The aim is to enroll approximately 500 patients between
the age of 18 and 80 years old. Eligible participants are
patients with histologically proven malignant melanoma
at high risk of recurrence namely in stage IB-III (stage
IA patients will not be included in the study because
they only have a very small chance of relapsing). Inclu-
sion in the study is only allowed after a complete resec-
tion of the melanoma has occurred. Participants are
included up to 1 year after diagnosis and after signing an
informed consent, which had been approved by the local
ethics committee. For detailed inclusion and exclusion
criteria see Appendix 1.
Materials
Participants randomized to the active treatment arm, will
receive 1 oral syringe filled with 4 ampoules of D-cure™
(Laboratories SMB NV, Brussels, Belgium), corresponding
to 100,000 IU cholecalciferol, on a monthly basis. Content
of 1 such ampoule is cholecalciferol 25,000 IU, DL-α-
tocopherol acetate, sorbitol oleate, orange peel oil and ara-
chis oil ad 1 ml. Participants randomized to the placebo
arm, will receive 1 oral syringe containing 4 ml arachis oil
(manufactured by Fagron, Waregem, Belgium).
Study drug administration and randomization
An independent site pharmacist prepares the medication.
A treatment and corresponding medication is assigned to
the patient during randomization. Medication is taken
monthly consisting of either a dose of 100,000 IU (4 ml of
D-cure™ suspension in arachis oil) or 4 ml of placebo (ara-
chis oil). The first intake of the drug is given immediately
at randomization in the hospital. Subsequent doses are
taken monthly at home and are registered in a patient
diary. Oral syringes are numbered according to the
randomization schedule. At each visit, 3 (if a control is
foreseen every 3 months in the university setting) or 6 sy-
ringes (if a control is only foreseen every 6 months in the
university setting and meanwhile by a peripheral derma-
tologist) are given to the patient. The date when the vita-
min D/placebo is taken and the number of syringes used
are registered. Empty syringes are destroyed.
Screening and randomization of patients
From Q4 2012 to Q4 2016 eligible stage IB-III melanoma
patients will be enrolled in our study. After staging, surgi-
cal treatment and signing an informed consent form, pa-
tients are screened and all in- and exclusion criteria (see
Appendix 1) verified. When deemed to be eligible, the
patient is randomized by the Leuven Coordinating
Centre (LCC, Leuven, Belgium) using an Interactive
Fig. 2. Study flow chart
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Voice Response System (IVRS) on an equal basis (1:1) to
either vitamin D or placebo group, stratified on time of
diagnosis (newly diagnosed, 0–6 months or 6–12 months
before start of the study) and centre. All study staff
members, trial nurses, dermatologists and patients are
blinded to the treatment allocation during the whole
study duration. The data management center keeps the
randomization schedule confidential. The study com-
plies with the Helsinki declaration of medical research
and is approved by the hospital medical ethics commit-
tees of the 4 participating centres.
Study conduct
At randomization a questionnaire is completed for every
participant with questions on melanoma risk factors,
including the amount and type of sun exposure and a
full skin examination for the assessment of phototype,
naevus phenotype and actinic damage is completed.
Body Mass Index (BMI) is estimated after measuring the
patient’s height and weight.
To monitor the effects of high dose vitamin D sup-
plementation, diagnostic tests and assays are per-
formed at regular time intervals. Serum 25(OH)D3
levels are measured at randomization and every
6 months subsequently. Every 3 months and at the end
of the study serum calcium and serum phosphate are
measured. Renal and liver function tests are evaluated
at randomization and at the end of the study. At the
end of the study, a 24-h urinary calcium excretion test
is done. For detailed information about schedule as-
sessments see Table 1. At randomization, the study
team will give the patient a diary in which to record
their use of drugs and side effects which are reviewed
by the clinician at follow-ups. Dose adherence of the
patients is controlled by recording the number of
empty syringes which the patients need to bring back.
Adherence to the study drug is improved by seeing the
patients at regular intervals (3 monthly) either by the
general practitioner, private dermatologist or at a
university hospital setting. Patients are followed until
relapse or end of study.
Safety
Baseline laboratory tests are performed at screening of
the patient and safety laboratory every 3 months of
follow-up. The parameters that are analyzed can be
found in Table 1. Laboratory parameters are only re-
ported as abnormal if the investigator assesses them as
‘clinically significant’ and/or when they result in precau-
tionary safety measures. The following laboratory values
will be reported as adverse events (AEs):
 Hypercalcemia: defined as 2 independent
measurements above the reference value as
defined by the laboratory where the sample
is determined (first measurement at the
investigational site and second measurement
at general practitioner/dermatologist)
 Hypervitaminosis D: defined as serum 25(OH)2D3
level > 80 ng/ml
 Hypovitaminosis D:
Deficient: serum 25(OH)2D3 < 10 ng/ml
Insufficient: serum 25(OH)2D3 ≥ 10 ng/ml
and <20 ng/ml
 Hypophosphatemia: defined as phosphate
level < 1.5 mg/dl
 Hyperphosphatemia: defined as phosphate
level > 6 mg/dl
Table 1 Schedule of assessments
Screening Randomization 3 monthly
FU
6 monthly
FU
End of study
25(OH)D3 serum levels X X
(when 25(OH)D3 levels >80 ng/ml and
study drug temporarily interrupted)
X
Blood sample for DNA analysis X
Hemoglobin, Hematocrit X X
WBC count and differentiation X X X
RBC count X X
Platelet count X X
Renal function (creatinine) X X
Liver function (AF, ALT, gamma-GT, LDH) X X
Serum calcium X X X
Serum phosphate X X X
Albumin X X
24 h urine calcium X
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Immunosuppressive effects are evaluated by reporting
the rate of infection every 3 months and by measuring
the total White Blood Cell (WBC) count and differential
every 6 months. For detailed information see Appendix
2. All AEs are documented by study investigators. An
AE is defined as any untoward medical occurrence in a
patient administered with an investigational medicinal
product and which does not necessarily have a causal
relationship with this treatment. Severity of AEs is
assessed (mild, moderate, severe or unknown). A Ser-
ious Adverse Event (SAE) is defined as any untoward
medical occurrence that at any dose results in death, is
life-threatening, requires inpatient hospitalization or
prolongation of existing hospitalization, results in per-
sistent or significant disability/incapacity, congenital
anomal/birth defect or is medically significant. SAEs
are documented within 24 h in the SAE module pro-
vided in the electronic Case Report Form (eCRF) and
reported to the LCC. All SAEs are monitored and
followed up until the outcome is known. The Data and
Safety Monitoring Board (DSMB) reviews all safety pa-
rameters and AEs. This board is composed of a derma-
tologist, an oncologist and biostatistician, who are all
not involved in the study and are unblinded. At regular
intervals, an unblinded interim analysis is performed to
assess the difference between the intervention arms and
to exclude an increase in relapse rate in the vitamin D
supplemented arm.
VDR expression in primary melanoma
The expression of the VDR is immunohistochemically
assessed in the primary tumor of each melanoma patient
that is enrolled in the study. This is done on formalin-
fixed paraffin embedded (FFPE) tissue that is collected at
diagnosis and is stored according to the standard proce-
dures of the department of pathology (Professor J. van
den Oord). FFPE slides from every melanoma are stained
on an autostainer (operational) using the Envision tech-
nique and a commercial monoclonal anti-VDR antibody.
The levels of VDR expression and their localization in
the different phases are semi-quantitatively assessed by
an experienced pathologist (Dr. C. aura).
Determination of 25-(OH)D serum levels
Serum 25(OH)D3 levels are determined at randomization
and every 6 months, using a commercially available radio-
immunoassay (RIA) kit: Diasorin, Stillwater, MN (USA) as
described [16]. This RIA is well accepted as a reference
protocol and commonly used to determine 25(OH)D3
levels in the field. The laboratory of “Experimental medi-
cine and Endocrinology” (Professor D. Vanderschueren)
has extensive experience in measuring 25(OH)D3 levels
and will therefore perform all these measurements [16].
The intra- and inter-assay coefficients of variation for
25(OH)D are 11% and 8% respectively. The detection of
the RIA kit is 5.0 nmol/L 25(OH)D. In addition, serum
25(OH)D3 levels will also be determined with an in
house liquid chromatography/tandem mass spectropho-
tometry method which is currently been developed and
validated in the diagnostic laboratory of the Leuven
University hospital.
DNA analysis
A bloodsample for DNA analysis is taken at randomization.
Genetic variants affecting vitamin D levels are genotyped
by using iPLEX technology. Multiple single nucleotide
polymorphisms (SNPs) have been reported to affect vita-
min D signaling. We analyse 4 common SNPs (rs12785878,
rs10741657, rs6013897 and rs7041), because they have the
most important effect on 25(OH)D3 levels. Fifteen candi-
date SNPs, located in genes in the vitamin D pathway and
previously reported to affect vitamin D signaling, are
selected as well. Those 15 SNPs may independently de-
termine 25(OH)D3 levels.
Participant follow-up
On a 3 monthly basis, there is a follow-up of all patients
included in the study. Consisting of physical examin-
ation, including full skin assessment and palpation of re-
gional lymph nodes and blood sample tests (see Table 1).
At intervals of 6 months (or upon clinical indication),
an ultrasound of the lymph nodes will be performed.
Only when new symptoms arise or physical findings
are suggestive for progression, a Positron Emission
Tomography-Computed Tomography (PET-CT) or Mag-
netic Resonance Imaging (MRI) is performed to exclude
distant metastasis. Every 12 months, an ultrasound of the
abdomen and x-ray of the chest (or CT thorax/abdomen
if clinically indicated) are performed.
Blinding
Both patients and investigators are blinded to study
medication and vitamin D levels.
Study duration
Patients enrolled in the study will be followed up through-
out the entire study duration, with a maximum of 3,5 years
follow-up. Participation of a patient may be terminated
earlier due to relapse/progression or due to a reasonable
cause, such as the investigator’s medical decision. At any
time, the patient has the right to withdraw consent with-
out a negative impact on her/his medical treatment. The
planned enrolment rate is 500 melanoma patients during
a recruitment phase of 4 years maximum. The first patient
was recruited in fall 2012 and the last patient will be
recruited in fall 2016. The study will stop 6 months after
the last patient is randomized. The study may terminate
earlier due to interruption of the DSMB, the sponsor,
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competent authorities/ethics committees or if the work is
not compliant with Good Clinical Practice.
Sample size justification
Assuming similar times to relapse as retrospectively ob-
served at the University hospital Leuven, 3 years of re-
cruitment and a total study duration of 3.5 years, 500
patients will have 90% power to detect a hazard ratio of
0.40 in favour of the vitamin D supplemented arm by
means of Cox proportional hazards model stratified for
time since diagnosis (3 strata: 0, 0–6 or 6–12 months
ago). The hazard ratio of 0.40 is in correspondence with
the intermediate effect size that was reported by
Newton-Bishop et al. [9] and a potential increase in VD
serum levels of 70 nmol/L, which is 80% of the ob-
served effect in a study with COPD patients [16]. It was
anticipated that no patient will be lost for follow-up.
Due to a slow recruitment, the recruitment period was
extended by 1 year.
Statistical methods
The primary analysis is an intent-to-treat analysis of all
randomized patients. Patients will be analysed according
to which treatment group they were randomized, irre-
spective of which study drug or even if any study drug
was received. A Cox proportional hazard model with
stratification for time since diagnosis (3 strata: 0, 0–6 or
6–12 months ago) will be performed to investigate the
difference between the two treatment groups for the pri-
mary endpoint, which is relapse-free survival. If the
treatment effect is stratum dependent, then the strata
will be analysed separately. A correction for baseline co-
variates like sex, age and the baseline vitamin D level
will be performed as sensitivity analyses. A Cox propor-
tional hazard model will also be used to investigate
whether a potential difference in relapse-free survival
between two treatment groups is different for VDR im-
munoreactivity and genetic variability in the vitamin D
pathway. The hazard ratios and associated 95%-confi-
dence intervals (CI) will be determined to assess the
contributions of significant factors. All reported p-values
will be two-sided, and a p-value less than 0.05 will be
considered statistically significant. A linear mixed model
will be used to identify the evolution of 25(OH)D3 levels
in function of genetic variability in the vitamin D path-
way. In order to examine the correlation between VDR
immunoreactivity and stage at diagnosis, a Kruskal-
Wallis test will be used. For newly diagnosed melanoma
patients, an analysis of variance will be performed to
correlate vitamin D levels at diagnosis, melanoma site
and subtype. Full details of the statistical analyses will be
described in a statistical analysis plan which will be final-
ized before database lock.
Quality assurance
All efforts are being made to reassure maximal quality
control. The study is performed according to good
manufacturing practices. Direct access to source data,
with strict adherence to all confidentiality regulations, is
available for monitoring purposes. In addition, a DSMB
reviews all safety parameters and AEs.
Discussion
To the best of our knowledge, this is one of the first ran-
domized, placebo-controlled phase III trial to examine
the efficacy and safety of long-term and high-dose vita-
min D supplementation in melanoma patients, with a
maximum time of supplementation of 3,5 years [17].
Patients are randomized in a 1:1 ratio, either receiving
100,000 IU cholecalciferol or placebo. The patients’ clin-
ical status, including adverse events, is monitored at
regular intervals. Blood tests and other technical investi-
gations are also regularly conducted as explained previ-
ously (see Table 1). There is a rising interest in vitamin
D with respect to its pleiotropic effects on chronic dis-
eases and cancer. The objective of the project is to build
further on the knowledge of these effects in the field of
melanoma treatment. Keeping in mind, the compro-
mised prognosis of patients with relapsing malignant
melanoma and the health as well as economic burden
associated with metastatic disease we consider vitamin
D supplementation a considerably save, low cost and
broadly acceptable adjuvant strategy worthwhile being
tested. If we can confirm our hypothesis that vitamin D
supplementation after removal of the tumor has a
protective effect on relapse of CMM, we may markedly
reduce the burden of CMM at several levels. Patients,
diagnosed with melanoma may have a better clinical
outcome, which not only means a decrease in loss of
years but also a decrease in loss of professional years
(decreased mortality in still professionally active young
population). Patients diagnosed with melanoma will
have an improved quality of life (less relapse, less com-
plications due to treatment of regional metastatic and
distant metastatic disease). Finally, there will be a de-
crease in health care costs related to treatment of re-
gional and distant metastatic disease.
Registration
The study is registered with Clinical Trial.gov
(NCT01748448). Eudract No: 2012–002125-30.
Protocol
A full copy of the protocol of the current ViDMe study
can be requested from the principal investigator Prof. Dr.
Marjan Garmyn, email: marjan.garmyn@kuleuven.be.
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Appendix 1
Inclusion and exclusion criteria for the ViDMe study
Inclusion criteria
1. Older than 18 years and younger than 80 years of age.
2. Histologically proven malignant melanoma, stage IB
to III. Not participating in another clinical trial.
3. The only treatment for melanoma is surgical
treatment.
4. Complete resection of melanoma.
5. Single primary invasive cutaneous melanoma
(inclusion within 1 year after diagnosis).
6. Signed ethical committee approved informed consent.
7. Serum phosphate and calcium at the entry of the
study within normal range of the laboratory reference.
Exclusion criteria
1. Pregnant/lactating women or planning on becoming
pregnant during the study.
2. Known hypersensitivity to vitamin D or its
components.
3. Pre-existing renal stone disease or chronic renal
disease.
4. Impaired renal function with an eGRF <30 mL/min/
1.73 m2 or renal dialysis.
5. Liver failure or chronic liver disease with liver
enzyme >2 fold the upper limit of normal.
6. History of parathyroid disease or granulomatous
disease (tuberculosis or sarcoidosis).
7. History of malabsorption syndrome or any medical
condition that might interfere with Vitamin D
absorption.
8. History of other malignancy within the last 5 years
except for carcinoma in situ of the cervix or basal
cell carcinoma or squamous cell carcinoma of the
skin or in situ malignant melanoma.
9. Chronic alcohol abuse.
10.Medical or logistic problems likely to preclude
completion of the study
Appendix 2
Safety procedures in the event of abnormal assay results
End of study
– Clinical significant hypercalcemia: defined as 2
independent measurements above the reference value
– Hypovitaminosis D (serum 25(OH)2D3 < 10 ng/ml)
– Pregnancy
– Disease progression
Action taken
– Hypervitaminosis D: Defined as 25(OH)2D3 > 80
ng/ml. Discontinue study drug and restart monthly
treatment with study drug when 25(OH)2D3 falls
below 50 ng/ml based on a 3 monthly monitoring.
– Hypovitaminosis D: serum 25(OH)2D3 > 10 ng/ml
and <20 ng/ml: supplementation of extra vitamin D
(D-cure): 25,000 IU/month
– Hypophosphatemia: < 1.5 mg/dl: further investigation
– Hyperphosphatemia: > 6 mg/dl: further investigation
Concomittant medications/treatments
Concomitant use of vitamin D or multi-vitamin supple-
ments, concomitant use of calcium supplements and
medications which we know interact with study medi-
cation are registered.
Other medications then listed below, will not be
recorded:
 Digoxin
 Lithium
 Thiazide diuretics
 Anticonvulsants
 Corticosteroids (Chronic oral use is an exclusion
criteria, topical use is permitted)
 H2 receptor antagonists
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